| Drug General Information |
| Drug ID |
D0C3AD
|
| Former ID |
DNC006358
|
| Drug Name |
GW-788388
|
| Drug Type |
Small molecular drug
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C25H23N5O2
|
| Canonical SMILES |
C1COCCC1NC(=O)C2=CC=C(C=C2)C3=NC=CC(=C3)C4=C(NN=C4)C5=C<br />C=CC=N5
|
| InChI |
1S/C25H23N5O2/c31-25(29-20-9-13-32-14-10-20)18-6-4-17(5-7-18)23-15-19(8-12-27-23)21-16-28-30-24(21)22-3-1-2-11-26-22/h1-8,11-12,15-16,20H,9-10,13-14H2,(H,28,30)(H,29,31)
|
| InChIKey |
SAGZIBJAQGBRQA-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Lck tyrosine kinase |
Target Info |
Inhibitor |
[1]
|
|---|
| Mitogen-activated protein kinase 14 |
Target Info |
Inhibitor |
[1]
|
| TGF-beta receptor type I |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Osteoclast differentiation
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
HTLV-I infection
|
|
Primary immunodeficiencyhsa04010:MAPK signaling pathway
|
|
Rap1 signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Neurotrophin signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Dopaminergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
GnRH signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Prolactin signaling pathway
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Influenza A
|
|
Epstein-Barr virus infection
|
|
Proteoglycans in cancerhsa04010:MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
TGF-beta signaling pathway
|
|
Hippo signaling pathway
|
|
Adherens junction
|
|
Hepatitis B
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Pancreatic cancer
|
|
Chronic myeloid leukemia
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
IL2 Signaling PathwayNetPath_17:IL5 Signaling Pathway
|
|
FSH Signaling Pathway
|
|
PANTHER Pathway
|
Parkinson disease
|
|
T cell activationP00003:Alzheimer disease-amyloid secretase pathway
|
|
Angiogenesis
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
FGF signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
Oxidative stress response
|
|
TGF-beta signaling pathway
|
|
Toll receptor signaling pathway
|
|
VEGF signaling pathway
|
|
Ras Pathway
|
|
p53 pathway feedback loops 2
|
|
p38 MAPK pathway
|
|
CCKR signaling map STP00052:TGF-beta signaling pathway
|
|
Pathway Interaction Database
|
Atypical NF-kappaB pathway
|
|
Glypican 1 network
|
|
TCR signaling in naï
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
Regulation of p38-alpha and p38-beta
|
|
TCR signaling in naï
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
IL2-mediated signaling events
|
|
CXCR4-mediated signaling events
|
|
Class I PI3K signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
amb2 Integrin signaling
|
|
EPHA forward signaling
|
|
PDGFR-beta signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Ephrin B reverse signaling
|
|
Alpha-synuclein signalingendothelinpathway:Endothelins
|
|
BCR signaling pathway
|
|
p73 transcription factor network
|
|
p38 MAPK signaling pathway
|
|
IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
CDC42 signaling events
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
FAS (CD95) signaling pathway
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
Glucocorticoid receptor regulatory network
|
|
Rapid glucocorticoid signaling
|
|
Regulation of Androgen receptor activity
|
|
ATF-2 transcription factor network
|
|
IL6-mediated signaling events
|
|
p38 signaling mediated by MAPKAP kinases
|
|
Retinoic acid receptors-mediated signaling
|
|
CXCR3-mediated signaling events
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
EPO signaling pathway
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
p53 pathway
|
|
S1P2 pathway
|
|
Trk receptor signaling mediated by the MAPK pathway
|
|
VEGFR3 signaling in lymphatic endothelium
|
|
FGF signaling pathway
|
|
RAC1 signaling pathway
|
|
Regulation of retinoblastoma proteinglypican_1pathway:Glypican 1 network
|
|
ALK1 signaling events
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
TGF-beta receptor signaling
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
PIP3 activates AKT signaling
|
|
Regulation of KIT signaling
|
|
Phosphorylation of CD3 and TCR zeta chains
|
|
Translocation of ZAP-70 to Immunological synapse
|
|
Generation of second messenger molecules
|
|
PECAM1 interactions
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
DAP12 signaling
|
|
CD28 co-stimulation
|
|
CD28 dependent PI3K/Akt signaling
|
|
CD28 dependent Vav1 pathway
|
|
CTLA4 inhibitory signaling
|
|
PD-1 signaling
|
|
Interleukin-2 signalingR-HSA-168638:NOD1/2 Signaling Pathway
|
|
p38MAPK events
|
|
ERK/MAPK targets
|
|
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
|
|
Oxidative Stress Induced Senescence
|
|
CDO in myogenesis
|
|
DSCAM interactions
|
|
ADP signalling through P2Y purinoceptor 1
|
|
Platelet sensitization by LDL
|
|
VEGFA-VEGFR2 Pathway
|
|
activated TAK1 mediates p38 MAPK activation
|
|
Activation of the AP-1 family of transcription factors
|
|
KSRP (KHSRP) binds and destabilizes mRNAR-HSA-2173789:TGF-beta receptor signaling activates SMADs
|
|
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
|
|
SMAD2/3 Phosphorylation Motif Mutants in Cancer
|
|
SMAD2/3 MH2 Domain Mutants in Cancer
|
|
TGFBR2 Kinase Domain Mutants in Cancer
|
|
TGFBR1 KD Mutants in Cancer
|
|
TGFBR1 LBD Mutants in Cancer
|
|
WikiPathways
|
Notch Signaling Pathway
|
|
Interferon type I signaling pathways
|
|
IL-2 Signaling Pathway
|
|
Inflammatory Response Pathway
|
|
Signaling by SCF-KIT
|
|
DAP12 interactions
|
|
Host Interactions of HIV factors
|
|
PIP3 activates AKT signaling
|
|
T-Cell Receptor and Co-stimulatory Signaling
|
|
B Cell Receptor Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
TCR signaling
|
|
Costimulation by the CD28 familyWP75:Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
TCR Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
MAPK Cascade
|
|
Oxidative Stress
|
|
p38 MAPK Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Kit receptor signaling pathway
|
|
Cardiac Hypertrophic Response
|
|
MAP kinase activation in TLR cascade
|
|
Regulation of mRNA Stability by Proteins that Bind AU-rich Elements
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
JAK/STAT
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Alpha 6 Beta 4 signaling pathway
|
|
Cardiac Progenitor Differentiation
|
|
BDNF signaling pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Parkinsons Disease Pathway
|
|
Corticotropin-releasing hormone
|
|
AGE/RAGE pathway
|
|
Prostate Cancer
|
|
TWEAK Signaling Pathway
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
IL-1 signaling pathway
|
|
Signal amplification
|
|
Platelet homeostasis
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Myogenesis
|
|
DSCAM interactions
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Angiogenesis
|
|
Physiological and Pathological Hypertrophy of the Heart
|
|
Regulation of toll-like receptor signaling pathwayWP560:TGF Beta Signaling Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Signaling by TGF-beta Receptor Complex
|
|
Integrated Breast Cancer Pathway
|
| References |
| REF 1 | J Med Chem. 2006 Apr 6;49(7):2210-21.Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. |
|---|
